No significant difference versus placebo observed for hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen
Your search for supplemental oxygen returned 14 results
Significant reductions seen in RSV-related infections, RSV-related hospitalizations for three monoclonal antibodies versus placebo
The studies evaluated routine clinical practice data from more than 800 hospitals in the US.
Actemra (tocilizumab) is an interleukin-6 receptor antagonist.
Kineret is an interleukin-1 receptor antagonist.
Lower average oxygen delivery rates seen in association with Asian, Black, Hispanic versus White race, ethnicity
The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.
Investigators report findings from a secondary analysis of the DARE-19 trial, which compared dapagliflozin with placebo in patients hospitalized with COVID-19.
The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.